Close Menu

People in the News

Sep 09, 2019

Celcuity: Eric Lindquist

Cell analysis company Celcuity has named Eric Lindquist its chief business officer. He had been global vice president of oncology and rare disease at Natera. Prior to that, he was global vice president of customer and companion diagnostics at Asuragen, as well as director of business development and alliances for companion diagnostics at Roche Diagnostics. 

Sep 09, 2019

Luminex: Dijuana Lewis

Luminex has elected Dijuana Lewis as an independent director to its board of directors, to the board's compensation and nominating committee, and to its corporate governance committee.

In a filing with the US Securities and Exchange Commission, Luminex reported that Lewis has served on various nonprofit and advisory boards and has consulted on healthcare related matters since her retirement from Aetna in April 2016.

She served Aetna as executive vice president, consumer products and enterprise marketing from October 2013 to April 2016. Prior to that, she served as senior vice president, health and wellness for Walmart Stores from March 2011 to October 2013. Further, Lewis previously served in a number of executive level positions of increasing responsibility with Anthem/Wellpoint from August 1994 to January 2011, including as the executive vice president and chief executive officer of its comprehensive health solutions division from October 2007 to January 2011.

Sep 06, 2019

Shield Diagnostics: David Esposito

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

Sep 06, 2019

BioMérieux: Kirk Ririe

Kirk Ririe, has retired from his position as bioMérieux's chief innovation officer and member of the firm's executive committee. Ririe will continue to act as a scientific advisor to the chairman and CEO.

Sep 05, 2019

Thermo Fisher Scientific: Debora Spar, Patrick Durbin, Gianluca Pettiti

Debora Spar has been elected as a director of Thermo Fisher Scientific. She is a professor of business administration at Harvard Business School. Previously, she was president and CEO of Lincoln Center for the Performing Arts and before that, president of Barnard College. Spar holds a PhD in government from Harvard University and a BSc from Georgetown University.

Also, Patrick Durbin, senior vice president at Thermo Fisher Scientific, has decided to leave the company, effective Oct. 1. He will be replaced by Gianluca Pettiti, president of the firm's biosciences business. Prior to that, Pettiti was president of Thermo Fisher China.

Sep 05, 2019

Todos Medical: Jorge Leon

Todos Medical has appointed Jorge Leon as a medical advisor to assist it with clinical development, regulatory strategy, and fundraising.

Leon holds a Ph.D. in cellular and molecular biology from New York University and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and Columbia University in New York. His subsequent academic research at Columbia University focused on developing monoclonal antibody-based tumor marker assays and radio-immunoimaging devices that are in wide use, according to Todos Medical.

In the early 1990s, Leon played an integral role in establishing and leading the molecular diagnostics laboratories at Quest Diagnostics. He spent 12 years developing Quest’s molecular diagnostics strategy as its director of molecular diagnostics, senior director of biotechnology development, and vice president of applied genomics.

In 2003, Leon founded Leomics Associates, a consulting firm established to help companies and academic institutions develop molecular diagnostics and personalized medicine products.

Sep 05, 2019

Farcast Biosciences: Maneesh Arora

Maneesh Arora has joined Boston-based diagnostics firm Farcast Biosciences as president and CEO. Arora previously served as COO and a member of the board of directors of Exact Sciences. He also previously was CFO of Third Wave Technologies, which was acquired in 2008 by Hologic for $582 million. Farcast, formerly called Mitra Biotech, has developed an ex vivo platform for evaluating tumor response to drug treatments.

Sep 03, 2019

ACMG: Maximilian Muenke

Maximilian Muenke has been named CEO of the American College of Medical Genetics and Genomics, succeeding Michael Watson. He will take up his new position on Oct. 7. Since 2000, Muenke has served as senior investigator, head of the human development section, and chief of the medical genetics branch at the National Human Genome Research Institute. Previously, he was a faculty member at the University of Pennsylvania. He holds an MD degree from the Free University of Berlin School of Medicine in Germany.

Aug 30, 2019

Lunaphore: Joseph Bernardo

Lausanne, Switzerland-based Lunaphore Technologies has appointed Joseph Bernardo chairman of its board of directors. Bernardo has a leadership background spanning the diagnostic value chain, including laboratory management, sales, service, marketing, distribution, operations, and R&D. Bernardo has held four president positions at Thermo Fisher Scientific, including in the divisions of Next Generation Sequencing, Immunodiagnostics, Anatomic Pathology, and Fisher Healthcare. In addition to his operational executive experience in diagnostics, Bernardo has significant M&A experience and has been involved in more than 40 due diligence assessments, acquisitions, and company integrations, Lunaphore said.

Aug 29, 2019

Natera: Rowan Chapman

Rowan Chapman has joined the board of directors of Natera. Most recently, she was head of Johnson & Johnson Innovation for Western North America, Australia, and New Zealand; head of precision diagnostics at GE Healthcare Life Sciences; and managing director of new business creation and head of healthcare investing at GE Ventures. Prior to that, she was a partner at Mohr Davidow Ventures. Chapman holds a BA in biochemistry and a PhD in biochemistry and molecular biology from the University of Cambridge.

Aug 29, 2019

Illumina: Garret Hampton

Garret Hampton, senior vice president of clinical genomics at Illumina, will be leaving the company effective Jan. 10, 2020 "in connection with an organizational restructuring," the company said this week in a document filed with the US Securities and Exchange Commission.

Aug 27, 2019

Ortho Clinical Diagnostics: Chris Smith

Ortho Clinical Diagnostics' board has appointed Chris Smith its CEO, effective Sept. 9. He succeeds Robert Yates who is stepping down as CEO but will remain as Ortho's non-executive chairman as a member of the company's board. Smith was most recently CEO of Cochlear Limited, a global medical device company based in Australia from 2015 to 2018. He also was president of Cochlear Americas for more than a decade. Before that, he held senior executive roles including CEO in residence for Warburg Pincus and global group president of Gyrus Group. Smith currently is on the board of several firms, such as Results Physiotherapy, Nyxoah, and Akouos. 

Pages